Search

Displaying results 3131 - 3140 of 10000 in total
  1. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [L43697] After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving … [L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies.

    Products: ACTEMRA (162 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE), ACTEMRA 162MG/0.9ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
  2. Drug

    Drotaverine

    go.drugbank.com/drugs/DB06751
    ApprovedWithdrawn

    [A231619] Drotaverine is not approved by the FDA, European Medicines Agency, or Health Canada. It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689] … Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4).

  3. Drug

    Alclometasone

    go.drugbank.com/drugs/DB00240
    Approved

    Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.

  4. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment … The drug is composed of an IL-6–binding trimer and a IgG-binding domain.

  5. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent … Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic

  6. Drug

    Asimadoline

    go.drugbank.com/drugs/DB05104
    Investigational

    It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases. … Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist.

  7. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    on PET images. … [L64052,L64053] It is the second fluorine-18 tau PET imaging agent approved in the United States, after flortaucipir (Tauvid), which was approved in 2020.[L64054,L14114]

  8. Drug

    Azatadine

    go.drugbank.com/drugs/DB00719
    ApprovedWithdrawn

    Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells.

  9. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. … TTP889 has proven to be effective in preventing clot formation in several animal models of human disease, without any signs of the bleeding associated with traditional anticoagulants.

  10. Drug

    Cystine

    go.drugbank.com/drugs/DB00138
    ApprovedInvestigationalNutraceuticalWithdrawn

    A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.